Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Amylyx Pharmaceuticals Raises $500 Million in Public Offering

PUBLIC · AMLXAug 19, 2026•2 days ago

Amount Raised

$500 Million

Round Type

Post-IPO Equity

CambridgeBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical

Investors

Life Sci Capital LlcGuggenheim Securities, LlcMorgan Stanley & Co. LlcLeerink Partners Llc

Description

On August 19, 2026, Amylyx Pharmaceuticals, Inc. completed an underwriting agreement for the issuance of 14,090,000 shares of common stock at $35.50 per share. The company also granted underwriters an option to purchase additional shares. This funding will support the company’s ongoing development of therapeutics for neurodegenerative diseases.

Company Information

Company

Amylyx Pharmaceuticals

Location

Cambridge, Massachusetts, United States

About

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investors.amylyx.com.

Don't miss Amylyx Pharmaceuticals's next move

Get an email the moment Amylyx Pharmaceuticals raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
1 contact
Verified contacts58 people are listed at Amylyx Pharmaceuticals. We don't have their email yet.
Predictive Intelligence
Strategic

ML-powered predictions for Amylyx Pharmaceuticals's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Amylyx Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.